Skip to content
DataLookout
Menu

COMBAT-HBVNCT05705427

The COMBAT HBV Feasibility Trial

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 16, 2026 Show 4 more changesShow less
    • Primary endpoints revised (10)
    • Eligibility criteria expanded, about 5 words
    • Enrollment target: 317 to 315
    • Secondary endpoints revised (2)
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Dec 2025 to Nov 25, 2025
    v7
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 560 to confirmed 317
    • Primary and study completion dates: Aug 2025 to Dec 2025
    • Site details revised
    v6
  4. Minor Primary and study completion dates: Jun 2025 to Aug 2025v5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2023 to Aug 17, 2023
    • Site details revised
    v4
  6. Notable Start date: Mar 2023 to Jul 2023
    • Primary and study completion dates: Dec 2024 to Jun 2025
    • Study description shortened, about 15 words
    v3
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety (Pregnant Women): Number of Women With Adverse Effects Related to Study Medications
Timeframe: Up to study close-out visit, or up to 6 months postpartum
Safety (Infants): Number of Infants With Adverse Effects Related to Study Medications
Timeframe: At delivery
Feasibility (Recruitment): Number of Eligible Participants Who Were Enrolled in the Study
Timeframe: Up to study close-out visit, or up to 6 months postpartum
Feasibility (Refusal): Number of Eligible Participants Who Refused to Enroll in the Study
Timeframe: Screening until end of enrollment eligibility period, up to 32 weeks gestation
Feasibility (Withdrawal): Number of Enrolled Participants Who Withdraw From the Study
Timeframe: Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)
Feasibility (Retention): Number of Enrolled Participants Who Remain in the Study Through 6 Months Postpartum
Timeframe: Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)
Feasibility (Maintenance): Mean Proportion of Study Visits Completed Per Maternal Participants
Timeframe: Up to study close-out visit, or up to 6 months postpartum
Acceptability (Lab Testing): Number of Mothers With Lab Testing Acceptability Scores >80%
Timeframe: Up to study close-out visit, or up to 6 months postpartum
Acceptability (Medication): Number of Mothers With Medication Acceptability Scores >80%
Timeframe: Up to study close-out visit, or up to 6 months postpartum
Preliminary Effectiveness: Number of Infants With HBV Positivity by Rapid Diagnostic Testing at 6 Months of Life to Indicate Mother-to-Child Transmission of HBV
Timeframe: Measured at 6 months after birth

Secondary (2)

Sensitivity of the Hepatitis B Core-Related Antigen Test Among Maternal Participants
Specificity of the Hepatitis B Core-Related Antigen Test

Arms and interventions

Tenofovir disoproxil fumarate (TDF) armExperimental

140 pregnant women in the experimental arm will receive tenofovir disoproxil fumarate (TDF) 300 milligrams (mg) daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine.

Placebo armPlacebo comparator

140 pregnant women in the placebo arm will receive a placebo pill daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine.

Drugs: Tenofovir Disoproxil Fumarate 300 MG, Placebo

Biologicals: Hepatitis B monovalent vaccine

Sites

1 site in 1 country

  • Université Protestant au CongoKinshasa, Democratic Republic of the Congo